Akero Therapeutics, Inc.
AKRODelisted Dec 9, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001744659
Akero Therapeutics, Inc. was delisted on Dec 9, 2025; its insiders filed their last Form 4 on Dec 9, 2025; 265 institutions reported holding it in 13F filings for Q3 2025, worth $4.34B in total; no superinvestor held it.
13F holders, Q1 2022
Institutional positions in Akero Therapeutics, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 103
- +6 vs. Q4 2021
- Shares held
- 35.2M
- −125.5K (−0.4%) vs. Q4 2021
- Total value
- $499.2M
- −$247.6M (−33.2%) vs. Q4 2021
- New holders
- 14
- 35 more added
- Sold out
- 8
- 25 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AKRO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $0 |
| Q1 2026 | 1 | $0 |
| Q4 2025 | 5 | $533.0K |
| Q3 2025 | 265 | $4.34B |
| Q2 2025 | 257 | $4.92B |
| Q1 2025 | 240 | $3.50B |
| Q4 2024 | 191 | $2.06B |
| Q3 2024 | 168 | $2.09B |
| Q2 2024 | 153 | $1.68B |
| Q1 2024 | 173 | $1.85B |
| Q4 2023 | 157 | $1.38B |
| Q3 2023 | 181 | $2.90B |
| Q2 2023 | 157 | $2.63B |
| Q1 2023 | 156 | $1.84B |
| Q4 2022 | 162 | $2.66B |
| Q3 2022 | 146 | $1.59B |
| Q2 2022 | 113 | $329.6M |
| Q1 2022 | 103 | $499.2M |
| Q4 2021 | 97 | $746.8M |
| Q3 2021 | 103 | $626.0M |
| Q2 2021 | 97 | $684.2M |
| Q1 2021 | 109 | $913.6M |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Akero Therapeutics, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Janus Henderson Group PLC | 3,368,662 | $47.8M | 0.02% | +205,040+6.5% | Added |
| Skorpios Trust | 4,907,829 | $69.6M | 18.54% | 00.0% | Unchanged |
| Federated Hermes, Inc. | 14 | – | – | +14 | New |
| Candriam Luxembourg S.C.A. | 0 | $0 | 0.00% | −88,876−100.0% | Sold out |
| TD Asset Management Inc | 0 | $0 | 0.00% | −25,102−100.0% | Sold out |
| IndexIQ Advisors LLC | 0 | $0 | 0.00% | −14,557−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −12,881−100.0% | Sold out |
| ProShare Advisors LLC | 0 | $0 | 0.00% | −10,529−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −4,082−100.0% | Sold out |
| Captrust Financial Advisors | 0 | $0 | 0.00% | −88−100.0% | Sold out |
| CoreCap Advisors, LLC | 0 | $0 | 0.00% | −50−100.0% | Sold out |